about
Survivin: a protein with dual roles in mitosis and apoptosisRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerNetwork-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer RiskTargeted anti-vascular therapies for ovarian cancer: current evidencePolo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancerExpression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathwayGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.Interleukin-6 as a therapeutic target in human ovarian cancerGene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) RiskParaneoplastic thrombocytosis in ovarian cancer.Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.Rethinking ovarian cancer: recommendations for improving outcomes.Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cellsFailure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo.Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian CancerCommon Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC).Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples.The peritoneal tumour microenvironment of high-grade serous ovarian cancer.The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis.Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene studyBRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian CancersIn vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume.Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity.
P50
Q24298568-F63016BB-CE6D-4F31-A86D-E51B91F26F9EQ26780387-CD169BF4-133D-4F50-9FAD-37EB903CA047Q26799669-1095ED6B-CF71-4DB8-A3D3-13762CE20BC1Q26830287-58B4872C-2452-49A3-B216-F03341C1C876Q27030815-69828B58-9718-4ED5-908D-811ED9AC53EDQ28204338-8C37C9D5-632A-48DC-9FCD-0BB5397C4233Q28388497-C2E1631C-831D-431C-9B45-D09D8EE56896Q28584533-32617A2F-65B7-403C-8898-035C48A8E65BQ30252854-453A0B57-E71C-4020-BE86-BAD8BD14EEDEQ30275832-18309968-3BFE-4D9B-B743-5583436ABEACQ30374367-CE592AF5-C0A3-407D-A422-D00B3DE0F133Q33829756-FAC0082A-E3AE-464D-BD09-3693DA79A179Q33997928-67BD9D10-55D9-46EA-92D8-98B249576A52Q34390396-1FD677FD-0703-4A1B-9874-FA4D8E440FE8Q34583808-68F83D2F-9E77-4BA4-9840-7CBEC1CEFD69Q34621683-C470413C-F717-4A83-902B-961088B49E8FQ34755147-8CB86FCE-0CAF-41B3-8BF1-32651CBBCFC3Q35239088-38F76236-7A9B-40E1-9FF9-071C77E5DE63Q35648549-61C8E69D-3F55-47EE-B456-C6CF62A221C2Q35668946-6A3357AD-7B98-4420-801E-1F9D380AEEA9Q35812402-4D2A836D-60F3-4DCA-BD88-604439CE1645Q35864258-9523898B-91B8-4ED7-96FF-6903C2003FB5Q36043441-FB61170C-C82B-4415-928C-303FA04977FBQ36050883-8483425B-0710-495C-AE44-7AA1430C6190Q36124728-016CE257-7AEA-4F54-B7F5-0050CF884BD0Q36139561-E98096CC-72C0-4F8C-8B69-E275B037D5A7Q36220647-31D8DC29-1AEF-47DA-9795-1446B038CEA2Q36255665-06764921-916B-4F6C-B22C-7A8AF756291CQ36472419-D1537E24-26D6-49C6-BE0A-C26099045310Q36490507-FE69C8AF-CA51-4820-BC09-9C22A9DE38B1Q36627211-70FD8002-4E97-4FC6-9DC2-04071DB26C89Q36719074-142ECC60-2B11-4F48-9EFA-342596997DBEQ36761574-5CA137DF-8F4A-4FFB-9CF9-535888D5C6AAQ36966218-8E71D811-564E-45AF-8421-2F1EFD14563CQ37002955-EBBED5FB-46F0-4D88-92DF-D6613378061BQ37232834-0AA55ACF-57FE-43C1-B2D4-71EC2CAA3C9BQ37285187-946937E6-CCDD-4757-BB3F-44DB5E85E1ABQ37448942-F69015B2-BC13-4ED8-95D9-000F2B08920DQ37495153-7964AEC3-2B67-4069-B39E-82275BBC562CQ37651981-AC90753C-7A1C-4601-9BE2-6DD0B82B3B89
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Iain A McNeish
@ast
Iain A McNeish
@en
Iain A McNeish
@es
Iain A McNeish
@nl
Iain A McNeish
@sl
type
label
Iain A McNeish
@ast
Iain A McNeish
@en
Iain A McNeish
@es
Iain A McNeish
@nl
Iain A McNeish
@sl
altLabel
Iain McNeish
@en
Ian McNeish
@en
prefLabel
Iain A McNeish
@ast
Iain A McNeish
@en
Iain A McNeish
@es
Iain A McNeish
@nl
Iain A McNeish
@sl
P108
P106
P31
P496
0000-0002-9387-7586